~~<i id='3C86195E03'><strike id='3C86195E03'><tt id='3C86195E03'><pre id='3C86195E03'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：fashion 2025-09-06 04:40:48 - browse：5775

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Synthetic human embryos? Researchers say term is overblown

explore

Wikipedia

explore

entertainment

leisure time

hotspot

BernardMossCourtesyNIAIDFormorethanhalfacentury,scientistBernardMosshasbeencommandingtheattentionofp

WSS

Biotech venture capitalists face new demands from investors

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

New brain studies show LSD's effects on the brain in full color

Copay coupons to count toward deductibles, after Biden court move

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

The simple reason for the increase in autism diagnosis

explore

leisure time

explore

Continuity nursing helped my family in our darkest PICU moments

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The high cost of giving birth even with insurance

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Novavax promises a turnaround & Lilly roils the obesity market

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Wikipedia

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Readout Newsletter: Merck, J&J, and long Covid

Brazil's Jair Bolsonaro is barred from running for office until 2030

Medicare Advantage today, explained in one chart

Eli Lilly, Pfizer, and others want in on the online prescription market

explore

entertainment

leisure time

hotspot